20/20 Biolabs, Inc. (AIDX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 250K 500K 750K Q1 '25: 553.8K Q2 '25: 535.1K Q1 '26: 353.4K Q2 '26: 730.6K Q1 '25 Q2 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 150K 300K 450K Q1 '25: 165.8K Q2 '25: 163.3K Q1 '26: 62.9K Q2 '26: 304.7K Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating Income Quarterly

-1.5M -1M -500K 0 500K 1M 1.5M Q1 '25: -772.2K Q2 '25: -845.7K Q1 '26: -1.4M Q2 '26: -1.2M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Net Income Quarterly

-2.4M -1.6M -800K 0 800K 1.6M 2.4M Q1 '25: -764.6K Q2 '25: -840.9K Q1 '26: -2.2M Q2 '26: -1.5M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 150K 300K 450K Q1 '25: 388K Q2 '25: 371.8K Q1 '26: 290.5K Q2 '26: 425.8K Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-1.5M -1M -500K 0 500K 1M 1.5M Q1 '25: -488.3K Q2 '25: -534.1K Q1 '26: -1.3M Q2 '26: -605.5K Q1 '25 Q2 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 4M 8M 12M Q1 '25: 4.8M Q2 '25: 4.8M Q1 '26: 7.7M Q2 '26: 10.8M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.